Advertisement

Advertisement

Breast Cancer

PADA-1 Trial: With Early Identification of ESR1 Mutation, Switch to Fulvestrant in Metastatic Breast Cancer

Switching from an aromatase inhibitor to fulvestrant upon early identification of the ESR1 mutation in plasma—before disease progression—doubled progression-free survival in the phase III PADA-1 trial, presented at the 2021 San Antonio Breast Cancer Symposium.1 “PADA-1 is the first trial to...

Breast Cancer
Genomics/Genetics
Immunotherapy

Expert Point of View: Angela DeMichele, MD, MSCE

Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is part ...

Breast Cancer
Genomics/Genetics
Immunotherapy

Dual Checkpoint Inhibitor Therapy Elicits Responses in Highly Mutated Breast Cancer

Patients with advanced HER2-negative metastatic breast cancer and high tumor mutational burden achieved responses—often durable—from treatment with the immunotherapy doublet of nivolumab and ipilimumab, according to results of the phase II NIMBUS trial reported at the 2021 San Antonio Breast Cancer ...

Breast Cancer
Genomics/Genetics

Expert Point of View: Mark E. Robson, MD

“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...

Breast Cancer
Genomics/Genetics

OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer

The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk ­early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...

Breast Cancer

Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer

New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...

Breast Cancer

EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer

Use of the first investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly reduced the risk of death or disease progression and lengthened progression-free survival compared with standard-of-care endocrine therapy with fulvestrant or an aromatase inhibitor in...

Breast Cancer

Aditya Bardia, MD, MPH, Comments on Findings From monarchE

The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...

Breast Cancer

Long-Term Follow-up of monarchE: Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer

Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy in the adjuvant treatment of early high-risk hormone receptor–positive, HER2-negative breast cancer, regardless of Ki67 index. The latest findings were reported at a ...

Breast Cancer

Long-Term Outcomes With Minimal-Access vs Conventional Breast Surgery in Stage 0 to III Breast Cancer

In a Chinese single-center, retrospective cohort, propensity score–matched analysis reported in JAMA Surgery, Wan et al found no difference in long-term outcomes, including distant metastasis–free and overall survival, with minimal-access breast surgery vs conventional breast surgery in women with...

Breast Cancer
Gynecologic Cancers
Colorectal Cancer
Issues in Oncology

Effect of Social Factors on Cancer Screening Rates Across U.S. Counties

Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...

Breast Cancer
Lung Cancer

Eligibility for Lung Cancer Screening Among Women With a Smoking History Undergoing Breast Cancer Screening

In a single-center retrospective cohort study reported in JAMA Network Open, Titan et al identified the proportion of women with a history of smoking undergoing breast cancer screening with mammography who were eligible for low-dose computed tomography (CT) lung cancer screening, as well as the...

Breast Cancer
Genomics/Genetics

Switch to Fulvestrant/Palbociclib With Rising ESR1 Mutation Level in Blood During Aromatase Inhibitor/Palbociclib Therapy in Patients With Advanced Breast Cancer

As reported in The Lancet Oncology by François-Clément Bidard, MD, and colleagues, the French phase III PADA-1 trial has shown that switching to fulvestrant/palbociclib vs continuing first-line aromatase inhibitor (AI)/palbociclib therapy was associated with improved progression-free survival among ...

Breast Cancer
Survivorship

C-Reactive Protein Level and Cognitive Function in Breast Cancer Survivors Aged 60 and Older

As reported in the Journal of Clinical Oncology by Carroll et al, an analysis from the Thinking and Living with Cancer Study has shown higher levels of C-reactive protein (CRP) at baseline and during follow-up among women with stage 0 to III breast cancer diagnosed at age ≥ 60 years vs controls,...

Breast Cancer

Decrease in Breast Cancer Mortality Rate Continues, but Gap Persists for Black Women: From American Cancer Society Report

Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...

Issues in Oncology
Breast Cancer

ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer Updated to Reflect New Trastuzumab Deruxtecan Data

Just 1 month after the DESTINY-Breast04 data were presented at the 2022 ASCO Annual Meeting Plenary Session,1 an ASCO expert panel released updated guidance that endorses the adoption of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) into clinical practice for patients with...

Breast Cancer
Immunotherapy

Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD

TROPiCS-02 is a statistically positive trial, with the primary endpoint met and also now with an overall survival gain of 3.2 months,” said the study’s invited discussant Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology, Barcelona. “TROPiCS-02 is...

Breast Cancer
Immunotherapy

TROPiCS-02: Sacituzumab Govitecan Improves Overall Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer

An overall survival benefit has now emerged for sacituzumab govitecan-hziy in women with previously treated, hormone receptor–positive/HER2-negative, locally recurrent, inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial.1 The...

Breast Cancer

Living With Metastatic Breast Cancer

After my first breast cancer diagnosis, in 2010, the odds for a cure were seemingly all weighted in my favor. A routine mammogram screening had picked up a small—less than 1 cm—mass in my right breast, and a tissue biopsy confirmed it was stage I estrogen receptor–positive breast cancer. I had no...

Breast Cancer

Single vs Multiple Doses of Prophylactic IV Antibiotics to Prevent Surgical Site Infection in Implant-Based Breast Reconstruction

In a Swedish study reported in JAMA Network Open, Gahm et al found that multiple vs single doses of prophylactic intravenous (IV) antibiotics did not significantly reduce the risk of surgical site infection leading to implant removal in women undergoing implant-based breast reconstruction after...

Breast Cancer
Geriatric Oncology

Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer

As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...

Breast Cancer

Association of Breast Cancer Recurrence in Patients Achieving pCR With vs Without Residual DCIS After Neoadjuvant Chemotherapy

In a retrospective analysis from the neoadjuvant I-SPY2 trial reported in JAMA Surgery, Osdoit et al found that among patients with breast cancer achieving pathologic complete response (pCR), there were no significant differences in treatment outcomes according to the presence or absence of...

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Constitutional BRCA1 Methylation and Risk of Triple-Negative Breast Cancer and Ovarian Cancer

In a case-control study within the U.S. Women’s Health Initiative (WHI) study population reported in JAMA Oncology, Lønning et al found that BRCA1 promoter methylation identified in white blood cells was associated with increased risks of incident triple-negative breast cancer and high-grade serous ...

breast cancer
immunotherapy

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).

Breast Cancer

Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals

An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...

breast cancer

Laurence Buisseret, MD, PhD, on Triple-Negative Breast Cancer: Chemoimmunotherapy With or Without an Anti-CD73 Antibody

Laurence Buisseret, MD, PhD, of Belgium’s Institut Jules Bordet, discusses phase II results from the SYNERGY trial, which tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer. Although adding oleclumab to durvalumab with chemoimmunotherapy did not increase the clinical benefit rate at week 24, research is ongoing to better understand the mechanisms of response and resistance to this study combination (Abstract LBA17).

Breast Cancer

Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs White Women With Breast Cancer

Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...

Breast Cancer

Reporting of Hispanic Ethnicity and Race in Breast Cancer Studies: National Cancer Database Analysis

In a National Cancer Database (NCDB) analysis reported in a research letter in JAMA Oncology, Bazan et al found that Hispanic ethnicity was reported in patient demographics or results in less than half of studies in breast cancer, with a smaller proportion categorizing race and ethnicity into...

Cost of Care
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer

Costs of Cancer Treatment for Younger, Privately Insured Patients

A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...

Breast Cancer
Cost of Care

Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure

In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...

breast cancer
survivorship

Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ovarian tissue cryopreservation in those not eligible for gamete cryopreservation); ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy; and long-term follow-up to improve the management of gynecology-related issues faced by these women.

Breast Cancer

Study Explores Link Between Use of Antipsychotic Agents and Increased Breast Cancer Risk

A research team from the Centre for Safe Medication Practice and Research (CSMPR) in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKUMed) conducted a systematic review and meta-analysis of observational studies with over 2 million individuals and estimated a moderate...

breast cancer
genomics/genetics

Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic breast cancer (Abstract 210O).

Breast Cancer

TROPiCS-02 Update: Sacituzumab Govitecan Improves Overall Survival in Previously Treated Patients With Hormone Receptor–Positive, HER2-Negative Breast Cancer

An overall survival benefit has now emerged for sacituzumab govitecan-hziy in patients with previously treated hormone receptor–positive/HER2-negative locally recurrent inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial. These...

Breast Cancer

T-DXd for Patients With HER2-Low Metastatic Breast Cancer: Patient-Reported Outcomes

Patients who received fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-low metastatic breast cancer reported that the treatment maintained their quality of life compared to conventional chemotherapy, according to results presented by Ueno et al at the European Society for Medical Oncology (ESMO)...

Breast Cancer

ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing

ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic...

Breast Cancer
Immunotherapy

Sacituzumab Govitecan in Pretreated Patients With Hormone Receptor–Positive, HER2-Negative Endocrine-Resistant Advanced Breast Cancer

As reported in the Journal of Clinical Oncology by Hope S. Rugo, MD, FASCO, and colleagues, the phase III TROPiCS-02 trial has shown a significant progression-free survival benefit with sacituzumab govitecan-hziy vs chemotherapy in previously treated patients with hormone receptor (HR)-positive,...

Breast Cancer
Symptom Management

Postmarketing Colitis Cases May Be Associated With Alpelisib Use

In a research letter in JAMA Oncology, Sullivan et al described details of postmarketing cases of noninfectious colitis in patients with breast cancer reported to the U.S. Food and Drug Administration that were considered possibly or probably related to alpelisib treatment. Key Findings A total of...

Breast Cancer

Report Finds 'Batwing' Mastopexy May Enable More Women to Undergo Nipple-Sparing Mastectomy

Nipple-sparing techniques can provide better outcomes for women undergoing breast reconstruction after mastectomy, but due to complication risks, these approaches are often not offered to women with sagging or larger breasts. For this group of patients, a “batwing” incision may provide a safer...

Breast Cancer
Survivorship

Fertility Preservation Procedures at Breast Cancer Diagnosis: Risk of Relapse and Disease-Specific Mortality

In a Swedish nationwide prospective cohort study reported in JAMA Oncology, Marklund et al found no increased risk of relapse or disease-specific mortality among women undergoing fertility preservation with or without hormonal stimulation at the time of breast cancer diagnosis. Study Details The...

Breast Cancer

Fertility Preservation Measures Do Not Appear to Increase the Risk of Breast Cancer Recurrence

Women with a breast cancer diagnosis undergoing procedures for fertility preservation are not at an increased risk for recurrence of the disease or disease-specific mortality, according to the results of a study from the Karolinska Institutet in Sweden that followed participants for 5 years on...

Breast Cancer
Genomics/Genetics

Researchers Identify Markers of Chemotherapy Resistance and Outcome in Patients With Triple-Negative Breast Cancer

Researchers have identified biological markers in patients with triple-negative breast cancer that are associated with resistance to chemotherapy. The study was published by Anurag et al in the journal Cancer Discovery and was funded by the National Cancer Institute’s Clinical Proteomics Tumor...

Breast Cancer
Survivorship
Supportive Care

Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer

For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...

Breast Cancer

APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years

Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...

Breast Cancer
Immunotherapy

T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer

In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...

Breast Cancer

WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS

As reported in The Lancet by Chua et al, the phase III BIG 3-07/TROG 07.01 trial has shown reduced risk of local recurrence with vs without tumor bed boost after conventional or hypofractionated whole-breast irradiation (WBI) in women receiving breast-conserving surgery for non–low-risk ductal...

Breast Cancer

Breast Induration Risk With Partial- vs Whole-Breast Irradiation After Breast-Conserving Surgery for Node-Negative Early Disease

As reported in the Journal of Clinical Oncology by Offersen et al, the phase III Danish Breast Cancer Group Partial Breast Irradiation Trial showed that partial-breast irradiation was noninferior to whole-breast irradiation in terms of the risk for breast induration in women aged ≥ 60 years...

Breast Cancer

Locoregional Recurrence With Predefined Risk-Based De-escalation of Radiotherapy After Primary Chemotherapy in cT1–2N1 Breast Cancer

As reported in The Lancet Oncology by de Wild et al, 5-year follow-up from a Dutch prospective registry study (RAPCHEM, BOOG 2010-03) showed low rates of locoregional recurrence with de-escalation of adjuvant radiotherapy according to predefined risk levels in women receiving primary chemotherapy...

Breast Cancer

Time to Initiation of Adjuvant Endocrine Therapy and Likelihood of Adherence in Medicaid-Insured Women With Breast Cancer

In a population-based retrospective cohort study reported in JAMA Network Open, Sood et al found that longer time to adjuvant endocrine therapy initiation in Medicaid-insured women with breast cancer was associated with a reduced likelihood of short- and long-term adherence to treatment. As stated...

Breast Cancer

Nivolumab Plus T-DXd Under Study in HER2-Expressing Metastatic Breast Cancer

In the phase Ib DS8201-A-U105 trial, the addition of the PD-1 inhibitor nivolumab to the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) did not appear to improve outcomes over T-DXd alone (based on historical controls). However, it did establish the safety of the combination,...

Advertisement

Advertisement

Advertisement